• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Greenhill & Co. Reports Third Quarter 2022 Results

    11/2/22 4:05:00 PM ET
    $GHL
    Investment Bankers/Brokers/Service
    Finance
    Get the next $GHL alert in real time by email
    • Quarterly revenues of $81.1 million, down slightly from prior year's third quarter
    • Year to date revenues of $162.6 million, down 19% from the same period in 2021 due to fewer transaction completions
    • Compensation ratio of 56% for the quarter; 83% for the year to date period, which is elevated as a result of lower year to date revenues
    • Non-compensation costs for the quarter down 7% and year to date down 3% despite increased travel and entertainment expenses
    • Operating margin of 28% for the quarter
    • Diluted earnings per share of $0.67 for the quarter and a loss per share of $0.91 year to date

    Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $81.1 million, net income of $14.2 million and diluted earnings per share of $0.67 for the quarter ended September 30, 2022.

    The Firm's third quarter 2022 revenues compare to revenues of $88.6 million in the third quarter of 2021, which represents a decrease of $7.5 million. The Firm's third quarter 2022 net income and earnings per share compare to net income of $20.1 million and diluted earnings per share of $0.85 for the third quarter 2021.

    For the nine months ended September 30, 2022, revenues of $162.6 million compare to $200.8 million for the comparable period in 2021, a decrease of $38.2 million. For the first nine months of 2022, a net loss of $16.6 million and a loss per share of $0.91 compare to net income of $13.4 million and diluted earnings per share of $0.55 for the same period in 2021.

    The Firm's revenues and net income can fluctuate materially depending on the number, size and timing of completed transactions on which it advised and other factors. Accordingly, the revenues and net income in any particular period may not be indicative of future results.

    "Our quarterly results are consistent with our commentary on the past two quarterly investor calls, when we said that we expected the year to play out similarly to the past three years, when a weak first half revenue result was followed by a much stronger second half performance, resulting in a respectable full year outcome. We continue to show appropriate discipline on costs, and thus are focused on delivering another year of solid cash flow generation. We continue to see our stock as significantly undervalued and, after a pause in the third quarter while our revenue expectations were confirmed despite turbulent markets, we recently began repurchasing shares," Scott L. Bok, Chairman and Chief Executive Officer, commented.

    Revenues

    Revenues were $81.1 million in the third quarter of 2022 compared to $88.6 million in the third quarter of 2021, a decrease of $7.5 million, or 8%. The decrease principally resulted from a decline in financing advisory and restructuring completion fees, offset in part by an increase in merger and acquisition transaction completion fees.

    For the nine months ended September 30, 2022, revenues were $162.6 million compared to $200.8 million in 2021, a decrease of $38.2 million, or 19%. The decrease principally resulted from a decline in restructuring completion and retainer fees.

    As of October 31, 2022, we have 79 client-facing Managing Directors. As of January 1, 2022, we also had 79 such Managing Directors.

    Expenses

    Operating Expenses

    Our total operating expenses for the third quarter of 2022 were $58.2 million, which compared to $58.3 million of total operating expenses for the third quarter of 2021. The slight decrease in total operating expenses of $0.1 million resulted from a decrease in our non-compensation operating expenses, partially offset by an increase in compensation and benefits expenses, each as described in more detail below. Our operating profit margin was 28% for the third quarter of 2022 as compared to 34% for the same period in 2021.

    For the nine months ended September 30, 2022, our total operating expenses were $175.1 million, which compared to $172.4 million of total operating expenses for the first nine months of 2021. The increase in total operating expenses of $2.7 million, or 2%, resulted from an increase in our compensation and benefits expenses, partially offset by a decrease in our non-compensation operating expenses, each as described in more detail below.

    The following table sets forth information relating to our operating expenses.

     

    For the Three Months Ended September 30,

     

    For the Nine Months Ended September 30,

     

    2022

     

    2021

     

    2022

     

    2021

     

    (in millions, unaudited)

    Employee compensation and benefits expenses

    $45.3

    $44.4

     

    $135.3

     

    $131.5

    % of revenues

    56%

    50%

     

    83%

    65%

    Non-compensation operating expenses

    12.9

     

    13.9

     

    39.8

    40.9

    % of revenues

    16%

    16%

     

    24%

    20%

    Total operating expenses

    58.2

    58.3

     

    175.1

    172.4

    % of revenues

    72%

    66%

     

    108%

    86%

    Total operating income (loss)

    23.0

    30.4

     

    (12.4)

    28.4

    Operating profit margin

    28%

     

    34%

     

    NM

    14%

    Compensation and Benefits Expenses

    Our employee compensation and benefits expenses were $45.3 million in the third quarter of 2022 as compared to $44.4 million for the third quarter of 2021. The increase in expense of $0.9 million, or 2%, was principally due to growth in professional headcount and a market driven increase in salaries. The ratio of compensation to revenues was 56% for the third quarter of 2022 as compared to 50% for the same period in the prior year. The ratio of compensation to revenues in the third quarters of 2022 and 2021 were adjusted lower than our annual targeted ratio in order to reduce the year to date ratio toward our targeted year end ratio.

    For the nine months ended September 30, 2022, our employee compensation and benefits expenses were $135.3 million compared to $131.5 million for the same period in 2021. The increase in expense of $3.8 million, or 3%, was principally attributable to headcount growth and higher salary levels of our professional staff. The ratio of compensation to revenues for the nine month period in 2022 was 83% as compared to 65% for the same period in 2021. The increase in the ratio of compensation to revenues for the nine month period in 2022 as compared to the same period in 2021 resulted from the effect of spreading slightly higher compensation and benefits expenses over lower revenues.

    Our compensation expense is generally based upon revenues and can fluctuate materially in any particular period depending upon changes in headcount, amount of revenues recognized, as well as other factors. Accordingly, the amount of compensation expense recognized in any particular period may not be indicative of compensation expense in a future period.

    Non-Compensation Operating Expenses

    For the three months ended September 30, 2022, our non-compensation operating expenses of $12.9 million decreased $1.0 million, or 7%, as compared to $13.9 million in the same period in 2021. The decrease principally resulted from the benefit of foreign currency gains and lower professional fees, partially offset by higher costs for business travel and entertainment and increased occupancy cost during the build out of a new London office.

    Non-compensation expenses as a percentage of revenues for the three months ended September 30, 2022 and 2021 remained constant at 16%.

    For the nine months ended September 30, 2022, our non-compensation operating expenses of $39.8 million decreased $1.1 million, or 3% as compared to $40.9 million in the comparable period in 2021. The decrease principally resulted from the benefit of foreign currency gains compared to foreign currency losses in the same period in the prior year, partially offset by increased travel and entertainment costs.

    Non-compensation expenses as a percentage of revenues for the nine months ended September 30, 2022 were 24% compared to 20% for the same period in 2021. The increase in non-compensation expenses as a percentage of revenues resulted from the effect of spreading lower non-compensation costs over much lower revenues in the first nine months of 2022 as compared to the same period in 2021.

    Our non-compensation operating expenses can vary as a result of a variety of factors such as changes in headcount, the amount of recruiting and business development activity, the amount of office expansion, the amount of client reimbursed expenses, the impact of currency movements and other factors. Accordingly, the non-compensation operating expenses in any particular period may not be indicative of the non-compensation operating expenses in future periods.

    Interest Expense

    For the three months ended September 30, 2022, we incurred interest expense of $4.4 million as compared to $3.0 million for the same period in 2021. The increase of $1.4 million principally related to higher market borrowing rates in the third quarter of 2022 compared to the same period in 2021, offset in part by lower borrowings outstanding.

    For the nine months ended September 30, 2022, we incurred interest expense of $10.4 million, an increase of $1.1 million as compared to $9.3 million for the same period in 2021. The increase related to higher average market borrowing rates, offset in part by lower average borrowings outstanding as a result of accelerated debt repayments made during 2021.

    The rate of interest on our borrowing is based on LIBOR and can vary from period to period. Accordingly, the amount of interest expense in any particular period may not be indicative of the amount of interest expense in future periods. There can be no certainty that our borrowing rate will not increase in future periods as a result of the transition from LIBOR to SOFR or another alternative rate.

    Provision for Income Taxes

    For the three months ended September 30, 2022, we recognized an income tax expense of $4.4 million, reflecting an effective tax rate of 24%. This compared to an income tax expense for the three months ended September 30, 2021 of $7.2 million, reflecting an effective tax rate of 26%. The decrease in the provision for income taxes in the third quarter of 2022 as compared to the same period in the prior year was attributable to lower pre-tax income and a slightly lower effective tax rate due to the generation of a greater proportion of earnings in the relatively low tax jurisdiction of the U.K. in 2022 as compared to 2021.

    For the nine months ended September 30, 2022, due to our pre-tax loss we recognized an income tax benefit of $6.2 million, which included an additional benefit of $0.8 million related to the tax effect of the vesting of restricted stock units at a market price higher than the grant price. This compared to income tax expense for the nine month period ended September 30, 2021 of $5.7 million, which included a charge of $0.7 million related to the tax effect of the difference between the grant price value and the market price value of restricted stock awards at the time of the vesting. Excluding these benefits/charges, the effective tax rates for the nine month periods ended September 30, 2022 and 2021 would have been 24% and 26%, respectively. The lower effective rate for the nine months ended September 30, 2022 is principally the result of a greater portion of earnings expected to be generated in the U.K. in 2022 as discussed above.

    The effective tax rate can fluctuate as a result of variations in the relative amounts of income earned and the tax rate imposed in the tax jurisdictions in which we operate. Accordingly, the effective tax rate in any particular period may not be indicative of the effective tax rate in future periods.

    Liquidity and Capital Resources

    As of September 30, 2022, we had cash and cash equivalents of $64.3 million and term loan debt with an outstanding principal balance of $271.9 million. The remaining principal balance of the term loan is due at maturity on April 12, 2024 and may be repaid further in advance of maturity without penalty.

    During the third quarter of 2022, we repurchased 28,691 restricted stock units from employees at the time of vesting to settle tax liabilities at an average price of $8.35 per share, for a total cost of $0.2 million. During the first nine months of 2022, we repurchased 812,094 restricted stock units from employees at the time of vesting to settle tax liabilities at an average price of $16.83 per share, for a total cost of $13.7 million.

    Additionally, in the first nine months of 2022 we repurchased in the open market 1,130,208 shares of our common stock at an average price of $14.84 per share for a total cost of $16.8 million.

    In aggregate for the year, as of September 30, 2022, we have repurchased 1,942,302 shares of our common shares and common stock equivalents at an average price of $15.67, for a total cost of $30.4 million. In addition, during October 2022 we repurchased 167,309 shares at $6.49 per share for a total cost of $1.1 million.

    For the twelve month period through January 31, 2023, our Board of Directors has authorized up to $70 million in purchases of shares and share equivalents (via tax withholding on vesting of restricted stock units). As of October 31, 2022, we have $43.3 million remaining under that authorization. Going forward, we intend to take a balanced approach to our use of available cash, allocating funds for a combination of deleveraging, share repurchases and dividends depending on such factors as our financial position, capital requirements, results of operations and outlook, as well as any legal, tax, regulatory or contractual constraints and any other factors deemed relevant.

    Dividend

    The Board of Directors of Greenhill & Co., Inc. has declared a dividend of $0.10 per share to be paid on December 21, 2022 to common stockholders of record on December 7, 2022.

    Investor Presentation

    An updated investor presentation highlighting the Firm's results for the third quarter and other matters relevant for investors has been posted on its website today (www.greenhill.com).

    Earnings Call

    Greenhill will host a conference call beginning at 4:30 p.m. Eastern Time on Wednesday, November 2, 2022, accessible via telephone and the internet. Scott L. Bok, Chairman and Chief Executive Officer, will review the Firm's third quarter 2022 financial results and related matters. Following the review, there will be a question and answer session.

    Investors and analysts may participate in the live conference call by dialing (888) 317 - 6003 (toll-free domestic) or (412) 317 - 6061 (international); passcode: 4557071. Please register at least 10 minutes before the conference call begins. The conference call will also be accessible as an audio webcast through the Investor Relations section of Greenhill's website at www.greenhill.com. There is no charge to access the call.

    For those unable to listen to the live broadcast, a replay of the call will be available for one month via telephone starting approximately one hour after the call ends. The replay can be accessed at (877) 344 - 7529 (toll-free domestic) or (412) 317 - 0088 (international); passcode: 2242982.

     

    Greenhill & Co., Inc. is a leading independent investment bank entirely focused on providing financial advice on significant mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments globally. It acts for clients located throughout the world from its offices in New York, Chicago, Frankfurt, Hong Kong, Houston, London, Madrid, Melbourne, Paris, San Francisco, Singapore, Stockholm, Sydney, Tokyo and Toronto.

    Cautionary Note Regarding Forward-Looking Statements

    The preceding discussion should be read in conjunction with our condensed consolidated financial statements and the related notes that appear below. We have made statements in this discussion that are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "intend", "predict", "potential" or "continue", the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks outlined under ‘‘Risk Factors'' in our Report on Form 10-K for the fiscal year 2021 as well as other public filings. We are under no duty and we do not undertake any obligation to update or review any of these forward-looking statements after the date on which they are made, whether as a result of new information, future developments or otherwise.

    Greenhill & Co., Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations (Unaudited)

    (In thousands, except share and per share data)

     

    For the Three Months Ended September 30,

     

    For the Nine Months Ended September 30,

     

     

    2022

     

     

    2021

     

     

    2022

     

     

     

    2021

    Revenues

    $

    81,145

     

    $

    88,646

     

    $

    162,635

     

     

    $

    200,807

     

     

     

     

     

     

     

     

    Operating Expenses

     

     

     

     

     

     

     

    Employee compensation and benefits

     

    45,265

     

     

    44,390

     

     

    135,277

     

     

     

    131,473

    Occupancy and equipment rental

     

    4,954

     

     

    4,628

     

     

    13,796

     

     

     

    13,625

    Depreciation and amortization

     

    635

     

     

    722

     

     

    1,880

     

     

     

    2,302

    Information services

     

    2,504

     

     

    2,476

     

     

    7,140

     

     

     

    7,161

    Professional fees

     

    1,774

     

     

    2,431

     

     

    5,971

     

     

     

    6,331

    Travel related expenses

     

    1,541

     

     

    815

     

     

    4,210

     

     

     

    1,523

    Other operating expenses

     

    1,492

     

     

    2,822

     

     

    6,782

     

     

     

    9,994

    Total operating expenses

     

    58,165

     

     

    58,284

     

     

    175,056

     

     

     

    172,409

    Total operating income (loss)

     

    22,980

     

     

    30,362

     

     

    (12,421

    )

     

     

    28,398

    Interest expense

     

    4,369

     

     

    2,985

     

     

    10,382

     

     

     

    9,271

    Income (loss) before taxes

     

    18,611

     

     

    27,377

     

     

    (22,803

    )

     

     

    19,127

    Provision (benefit) for taxes

     

    4,400

     

     

    7,233

     

     

    (6,176

    )

     

     

    5,724

    Net income (loss)

    $

    14,211

     

    $

    20,144

     

    $

    (16,627

    )

     

    $

    13,403

     

     

     

     

     

     

     

     

    Average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    17,935,848

     

     

    19,046,407

     

     

    18,197,533

     

     

     

    19,387,582

    Diluted

     

    21,095,880

     

     

    23,751,697

     

     

    18,197,533

     

     

     

    24,192,080

    Earnings (loss) per share:

     

     

     

     

     

     

     

    Basic

    $

    0.79

     

    $

    1.06

     

    $

    (0.91

    )

     

    $

    0.69

    Diluted

    $

    0.67

     

    $

    0.85

     

    $

    (0.91

    )

     

    $

    0.55

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006044/en/

    Get the next $GHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHL

    DatePrice TargetRatingAnalyst
    4/28/2022$16.50 → $12.00Mkt Perform → Underperform
    Keefe Bruyette
    3/9/2022$18.50 → $17.00Neutral
    Piper Sandler
    7/14/2021$15.50Underperform → Market Perform
    Keefe, Bruyette & Woods
    More analyst ratings

    $GHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co. Reports Second Quarter 2023 Results

      Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share Quarterly revenues of $71.4 million, up 98% from prior year's second quarter Year to date revenues of $121.1 million, up 49% from the same period in 2022 Compensation ratio of 54% for the quarter; 82% for the year to date period Operating margin of 21% for the quarter Recruited two additional Managing Directors during the quarter Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023. The Firm's second quarter

      8/9/23 4:05:00 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Greenhill downgraded by Keefe Bruyette with a new price target

      Keefe Bruyette downgraded Greenhill from Mkt Perform to Underperform and set a new price target of $12.00 from $16.50 previously

      4/28/22 6:12:12 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Piper Sandler reiterated coverage on Greenhill & Co with a new price target

      Piper Sandler reiterated coverage of Greenhill & Co with a rating of Neutral and set a new price target of $17.00 from $18.50 previously

      3/9/22 6:45:52 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co upgraded by Keefe, Bruyette & Woods with a new price target

      Keefe, Bruyette & Woods upgraded Greenhill & Co from Underperform to Market Perform and set a new price target of $15.50

      7/14/21 5:05:57 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Financials

    Live finance-specific insights

    See more

    $GHL
    SEC Filings

    See more

    $GHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co. Reports Second Quarter 2023 Results

      Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share Quarterly revenues of $71.4 million, up 98% from prior year's second quarter Year to date revenues of $121.1 million, up 49% from the same period in 2022 Compensation ratio of 54% for the quarter; 82% for the year to date period Operating margin of 21% for the quarter Recruited two additional Managing Directors during the quarter Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023. The Firm's second quarter

      8/9/23 4:05:00 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form 15-12G filed by Greenhill & Co. Inc.

      15-12G - GREENHILL & CO INC (0001282977) (Filer)

      12/11/23 4:03:05 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form S-8 POS filed by Greenhill & Co. Inc.

      S-8 POS - GREENHILL & CO INC (0001282977) (Filer)

      12/1/23 8:44:25 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form S-8 POS filed by Greenhill & Co. Inc.

      S-8 POS - GREENHILL & CO INC (0001282977) (Filer)

      12/1/23 8:41:52 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Ferro Kevin returned 81,495 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:08:03 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Wyles David returned 98,707 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:05:56 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Ekman Ulrika returned 10,205 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:03:36 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13G/A - GREENHILL & CO INC (0001282977) (Subject)

      7/17/23 4:18:36 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13D/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13D/A - GREENHILL & CO INC (0001282977) (Subject)

      5/22/23 5:28:29 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13G/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13G/A - GREENHILL & CO INC (0001282977) (Subject)

      1/9/23 11:41:53 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance